Drug Profile
Albumin/insulin
Alternative Names: Albulin; Albulin-G; Albumin/insulin fusion protein; Insulin analogue - Teva; Long-acting insulin - TevaLatest Information Update: 14 Nov 2013
Price :
$50
*
At a glance
- Originator Human Genome Sciences
- Developer Teva Pharmaceutical Industries
- Class Antihyperglycaemics; Insulins
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 14 Nov 2013 Discontinued - Phase-I for Type-1 diabetes mellitus in USA (SC)
- 14 Nov 2013 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (SC)
- 22 Feb 2008 CoGenesys has been acquired and merged into Teva Pharmaceutical Industries